Can-Fite BioPharma (CANF) announced that a patient treated with Namodenoson has reached an overall survival of 9 years to date with complete response to treatment. The patient, who suffered from advanced liver cancer, was enrolled in Can-Fite’s completed Phase II study and continues to be treated with Namodenoson through a compassionate use program. Nine years following treatment, the patient remains cancer-free and meets the definition of a complete responder based on the disappearance of ascites, normal liver function, and good quality of life.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CANF:
- Can-Fite BioPharma Shareholders Approve Key Proposals
- Buy Rating for Can-Fite BioPharma: Promising A3AR Agonists in Psoriasis and Liver Cancer with Strong Safety Profile
- Can-Fite BioPharma assumed with a Buy at H.C. Wainwright
- Can-Fite BioPharma Reschedules Shareholder Meeting Due to Lack of Quorum
- Can-Fite BioPharma’s Phase 3 Psoriasis Study: A Potential Game Changer?